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Review Article
Chronic respiratory failure in patients with neuromuscular 
diseases: diagnosis and treatment*
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Abstract
Neuromuscular diseases affect alveolar air exchange and therefore cause chronic respiratory failure. The onset of respiratory failure can 
be acute, as in traumas, or progressive (slow or rapid), as in amyotrophic lateral sclerosis, muscular dystrophies, diseases of the myoneural 
junction, etc. Respiratory muscle impairment also affects cough efficiency and, according to the current knowledge regarding the type of 
treatment available in Brazil to these patients, it can be said that the high rates of morbidity and mortality in these individuals are more 
often related to the fact that they cough inefficiently rather than to the fact that they ventilate poorly. In this review, with the objective of 
presenting the options of devices available to support and substitute for natural ventilation in patients with neuromuscular diseases, we have 
compiled a brief history of the evolution of orthoses and prostheses used to aid respiration since the end of the 19th century. In addition, we 
highlight the elements that are fundamental to the diagnosis of alveolar hypoventilation and of failure of the protective cough mechanism: 
taking of a clinical history; determination of peak cough flow; measurement of maximal inspiratory and expiratory pressures; spirometry 
in two positions (sitting and supine); pulse oximetry; capnography; and polysomnography. Furthermore, the threshold values available in 
the literature for the use of nocturnal ventilatory support and for the extension of this support through the daytime period are presented. 
Moreover, the maneuvers used to increase cough efficiency, as well as the proper timing of their introduction, are discussed.
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Introduction
Neuromuscular diseases lead to alveolar hypov-
entilation. When the onset is slow and progressive, 
alveolar hypoventilation typically goes undiagnosed 
and untreated until an episode of acute respira-
tory failure occurs. This episode of decompensation 
is frequently seen during common upper airway 
infections, and it results from patient incapacity to 
eliminate secretions.
Respiratory muscle strength impairment can 
occur in various neuromuscular diseases (Chart 1).
In cases of cervical spine trauma, the loss of respi-
ratory capacity is acute and irreversible. When 
muscular dystrophies, neurological disorders and 
myoneural junction diseases affect the respiratory 
muscles, they present an evolution of a different 
sort, presenting outbursts, or progressive worsening, 
at varying rates of speed.
The progressive form of respiratory muscle 
impairment produces blood gas alterations 
(hypoxemia and hypercapnia, both resulting from 
hypoventilation). Only when the lungs present 
lesions caused by repeated infections as a result of 
inefficacious coughing and episodes of aspiration 
due to uncoordinated swallowing, can hypoxemia 
also be explained as the result of ventilation-
perfusion mismatching. The initial management of 
a neuromuscular disease patient with hypoxemia 
and hypercapnia does not necessarily involve the 
use of oxygen but must include techniques aimed 
at re-establishing appropriate alveolar air exchange. 
Indeed, using oxygen alone in situations of hypov-
entilation can lead to the death of the patient.
History: the evolution of 
mechanical ventilators
The use of devices that perform the functions 
of the respiratory system constitutes an important 
chapter in the history of medicine and one about 
which physicians in general, and even pulmonolo-
gists, have little knowledge.
The interaction of the elastic forces of the chest 
cavity and the lung produces a subatmospheric 
pressure between these two structures and trans-
forms the chest into a very peculiar organic cavity, 
different from the cranial cavity and abdominal 
cavity, which do not present this pressure-related 
peculiarity.
One persistent obstacle to opening the chest 
cavity for therapeutic purposes was that of the lower 
intrathoracic pressure, which made it impossible to 
establish communication between the interior and 
exterior of the cavity without compromising the 
lungs and thus causing their collapse.
Chart 1 - Neuro-skeletal muscle conditions that can lead to chronic hypoventilation.
Myopathies
Muscular dystrophies
Duchenne and Becker dystrophies
Other muscular dystrophies, such as limb-girdle, 
Emery-Dreifuss, facioscapulohumeral, congenital, autosomal 
recessive, myotonic dystrophy
Non-Duchenne
myopathies
Metabolic or congenital myopathies
Inflammatory myopathies (polymyositis, associated with 
connective tissue diseases or other systemic diseases)
Diseases of the myoneural junction, such as myasthenia gravis
Myopathies associated with traumas or medications
Neurological diseases
Spinal muscular atrophy Neuropathies (hereditary, acquired, Guillain-Barré syndrome)
ELA-type motor neuron 
diseases
Myelopathies
Poliomyelitis Supraspinal tonus disorders
Multiple sclerosis
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It took a long time to reach the understanding 
of the very fact that the pressures are different. One 
of the pioneers of the physiology of ventilation, 
the German surgeon Sauerbruch,(1) only began to 
unravel this mystery at the end of the 19th century. 
In his attempts to open the chest, he concluded that 
the pressure in the interior of the chest cavity was 
lower than the atmospheric pressure and, in addi-
tion, that this fact was fundamental for respiration.
In order to circumvent this difficulty created by 
the pressure difference, Sauerbruch(1) developed a 
chamber for chest surgery (Figure 1). In this chamber 
that he created, the patient about to undergo 
surgery was positioned with the head outside the 
chamber, under the care of the anesthesiologist. The 
surgical team and the remaining part of the body 
of the patient stayed inside the chamber, where the 
pressure produced by air suction pumps was lower 
than the atmospheric pressure by approximately 
7 mmHg. Communication between the interior and 
exterior sides of the chamber was sealed around the 
neck of the patient by a sort of adjustable mobile 
sealer clip. The head outside the chamber and the 
subatmospheric pressure around the chest permitted 
the opening of the chest without collapse of the 
lungs, maintaining spontaneous ventilation.
The first device designed as a substitute for spon-
taneous ventilation in individuals who, for some 
reason, no longer present adequate recirculation of 
air in the alveolar spaces, came to be widely used in 
the USA beginning in the 1930s. Built by an engineer 
in the Hospital of Harvard University,(2) it was dubbed 
the iron lung. At that time, there was a poliomyelitis 
pandemic, in which many people died from the para-
lytic respiratory form of the disease, due to the fact 
that there was no mechanism available that could be 
used as a substitute for ventilation. The need for a 
machine that could ventilate patients was imperative, 
and the knowledge of respiratory physiology avail-
able at that time led to the construction of this device 
(the iron lung), which was similar to the Sauerbruch 
chamber. It consisted of a steel cylinder, enclosing 
the body of the patient up to the neck, leaving only 
the head outside the chamber, and was powered by 
an electric motor that periodically generated subat-
mospheric pressure inside the cylinder, provoking the 
expansion of the chest cavity. This volume increase 
of the chest caused the intrathoracic pressure to 
drop and the air to be aspirated into the airways. 
Curiously, when the machine had to be temporarily 
a
b
c
Figure 1 - Devices developed by Sauerbruch for 
performing thoracic surgery in a hypobaric chamber: 
a) Experimental negative pressure apparatus; b) Surgeon 
inside the hypobaric chamber; and c) Divider for the 
creation of the hypobaric chamber.
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shut off, a transparent dome was placed over the 
head of the patient, within which positive pressure 
was produced. A similar positive pressure device was 
described by Sauerbruch in his book, published in 
1922(1) (Figure 2), although the author frankly stated 
that he preferred the negative pressure chamber, his 
creation, for fear of the hazardous effects that posi-
tive pressure might have on the lungs.
The difficulty in providing general care, such 
as bathing, feeding and medicating patients in 
iron lungs can be foreseen. In addition, the forced 
immobility and the impossibility of coughing have 
certainly resulted in innumerable infectious pulmo-
nary complications. Despite their shortcomings, 
there was a great demand for iron lungs, and their 
availability was limited in many hospitals.
In the summer of 1952, the poliomyelitis 
epidemic claimed many victims in Copenhagen, 
Denmark. Numerous patients presented respiratory 
difficulties, and the only ventilators available were a 
few negative pressure cuirass ventilators (iron lung-
type ventilators that encircle only the chest), which 
are incapable of totally substituting the ventilation 
of the patients. The anesthesiologist Bjorn Ibsen 
was called upon to give his expert opinion regarding 
the treatment of the patients, and submitted one 
of them to a tracheostomy,(3) using a device known 
as an Ambu bag for ventilation. He proved that the 
invasive technique was more efficient in removing 
carbon dioxide than was the noninvasive tech-
nique. After the demonstration given by Ibsen, this 
form of ventilation became the standard treatment 
for the respiratory paralysis form of poliomy-
elitis in Denmark. Approximately 1500 Medicine
and Dentistry students were summoned to take 
turns working six hour-shifts in the ventilation of 
patients with Ambu bags and logged approximately 
165,000 h of service, saving the lives of many people 
through their considerable efforts.(3)
When the poliomyelitis epidemic arrived in 
Sweden the following summer, the Swedes already 
had a mechanical ventilator that, similarly to Ambu 
bag, injected air under pressure into the airways, but 
did not require the helping hands of the volunteers. 
Therefore, positive pressure ventilators appeared, 
becoming the standard treatment in acute respira-
tory failure in the years to follow. 
The criteria and parameters for the injection 
of pressurized gas into the airways have been 
a constant cause for concern since the 1960s. 
Ensuring a sufficient tidal volume for the patient, 
without damaging the lung due to the excessive 
pressure peaks, was one of the first aspects studied 
and inspired the development of volume control 
ventilators with pressure alarms. Inflating the lungs 
to a certain predetermined airway pressure proved 
insufficient to adequately ventilate the patient, 
especially in those with lung disease. Decreased 
pulmonary compliance caused cycling pressure to 
be reached in a very short time, insufficient for the 
influx of an appropriate tidal volume.
Another fundamental discovery in the area of 
mechanical ventilation was related to the need to 
maintain the alveoli open throughout the respiratory 
cycle, since there is a greater than normal tendency 
for the alveoli to collapse in some pathological 
conditions. Since 1969,(4) positive end-expiratory 
pressure has been considered a mandatory tech-
nique in artificial ventilation. Even for inspiration, 
it has been demonstrated that the maintenance of 
a pressure plateau, at the end of the gas injection, 
improves the distribution of the gas mixture to the 
millions of alveoli and favors hematosis.
Subsequently, attention was turned to the 
ventilation of individuals who have partially recov-
ered from acute respiratory failure and need to 
be ‘weaned’ from mechanical ventilation. In this 
phase, the patients were required to be awake and 
cooperative, only being assisted by the machine 
during ventilation. Under such circumstances, it 
was fundamental that the process of gas injection 
be comfortable and that the ventilatory work could 
be gradually resumed by the patient. Within this 
context, a great advance was made in the 1980 s: 
Figure 2 - Positive pressure apparatus, according to 
Sauerbruch.
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the development of the type of ventilation denomi-
nated pressure support ventilation.(5) This is a form 
of spontaneous ventilation that is flow-triggered, 
pressure-limited and flow-cycled.
The treatment of acute respiratory failure long 
monopolized the attention of many researchers, and 
few were concerned about patients with chronic 
respiratory failure.(6-8) The need for alternatives 
means of caring for such patients in environments 
other than intensive care units led to the develop-
ment of machines with specific characteristics, to be 
used in places where a source of gas under pressure 
is not available. In 1978, the first portable ventila-
tors, which were independent from pressurized gas 
networks, became available.(7) These ventilators can 
generate flow from room air, using compressors 
or turbines. In most cases, these ventilators have 
internal batteries or can be connected to an external, 
continuous power source (car battery, uninterrupted 
power supply, etc.).
At that time, quadriplegic patients with zero 
vital capacity were preferentially treated through 
tracheostomy and volume-cycled ventilators for 
home use. Tracheostomy permitted the satisfactory 
management of secretions, since the patient was 
unable to cough. In addition, it also prevented, for 
some time, the aspiration of the contents of the 
mouth or oropharynx in cases of concomitant swal-
lowing disorders.
However, the tracheostomy maintained for years 
is associated with innumerable complications,(7)
such as infections, increased quantity of secretion, 
impaired mucociliary clearance and bleeding, as well 
as sudden death resulting from a secretion plug or 
from the accidental disconnection of the device.
Other situations that lead to chronic respiratory 
failure, but are progressive, such as neuromuscular 
diseases and alterations of the chest wall, make it 
difficult to determine the appropriate moment at 
which to perform a tracheostomy, and patients 
would benefit considerably from an alternative 
method that would prevent or indefinitely postpone 
this intervention.
In 1976, noninvasive treatments for respiratory 
problems begin to be mentioned.(9) The procedure 
described, carried out with positive pressure, was 
designated continuous positive airway pressure 
(CPAP) and involves the use of a nasal or oronasal 
mask. However, although CPAP maintains the 
airways open and can decrease alveolar collapse, 
it does not provide ventilatory support. This tech-
nique became popular as a home-based treatment 
for obstructive sleep apnea.
Data published since 1987 provide a record of 
the use of noninvasive ventilation since the 1960 s
in patients with post-poliomyelitis syndrome or 
other neurological disorders.(10-12) These patients 
used volume-cycled ventilators, in the assist/control 
mode, using mouthpieces that permitted inspiration 
at the desired moment.
The adaptation of pressure support to nonin-
vasive forms of ventilation was reported in 1990, 
when a system was devised to be used with an 
oronasal mask, dependent on a pressurized gas 
network, a fact that limited its use to hospital 
environments.(13)
A pressure-cycled respirator has little chance of 
maintaining ventilation at an appropriate level when 
used in a noninvasive manner. This incapacity is due 
to the form of its pressure wave, which does not 
present any type of plateau: the pressure rises to a 
pre-determined value and then drops rapidly back 
to the baseline. In addition to this characteristic, 
this respirator does not compensate for air leakage 
around the nasal or oronasal mask. In pressure 
support, ventilation is pressure-limited: when the 
adjusted value for the support is reached, the flow 
does not stop, just decreases, in order to maintain 
constant pressure, despite the progressive increase 
in lung volume. This particularity creates a pressure 
plateau that is responsible, in great part, for the 
good results in the improvement of ventilation.
In 1990, some authors(14) described a new form 
of treating sleep apnea, using two pressure levels: 
a higher value for inspiratory positive airway pres-
sure (IPAP) and a lower value for expiratory positive 
airway pressure (EPAP). The machine worked as a 
continuous flow generator, capable of detecting 
the respiratory stimulus of the patient, upon which 
it would rapidly raise the pressure in the circuit to 
the IPAP level chosen. This pressure was maintained 
during all the inspiration, and the reduced flow, back 
to the chosen level of expiratory pressure (EPAP), 
occurred concomitantly with the decreased flow 
demand by the patient. The system was denomi-
nated the bi-level positive airway pressure (BiPAP) 
ventilator, and its technical characteristics allowed it 
to work in a manner very similar to that of pressure 
support ventilators, except that it was independent 
from a source of gas under pressure.
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The accumulation of secretion or conditions that 
reduce pulmonary compliance can compromise the 
efficiency of this type of equipment in improving 
ventilation, and this can be a significant limitation 
to its use in the pressure support of individuals with 
chronic respiratory failure. However, experience has 
shown that the increased pressure support (up to 
30 cmH2O) and efficient physical therapy techniques 
for the elimination of sputum broaden the applicability 
of the BiPAP (although the name is the trademark of 
a machine, it has come to signify a type of ventila-
tory support). Therefore, the application of BiPAP was 
expanded from the treatment of sleep apnea to a wide 
variety of situations in which its extremely comfortable 
standard of managing flow constitutes an advantage. 
This comfort is quite important whenever the patient 
still maintains some capacity of spontaneous ventila-
tion, since, in these cases, square-wave flow patterns 
are hard to support.
In this brief history, we can observe the oscilla-
tion of basic concepts in the substitution for or aid 
to ventilation: ‘respiratory orthoses and prostheses’ 
were initially noninvasive, later being exclusively 
invasive, and currently providing a wide variety of 
options. The improvement of ventilation of a patient 
with neuromuscular disease demands appropriate 
knowledge from the doctor, so that they can decide 
what technique is better for the functional state of 
that patient.
Evaluation of the evolution 
of respiratory impairment in 
neuromuscular diseases
The progression of respiratory complications 
to chronic respiratory failure in patients with 
neuromuscular diseases generally occurs as a direct 
consequence of two principal factors: weakness/
fatigue of respiratory muscles (inspiratory, expira-
tory and of the upper airways); and incapacity to 
maintain the airways free of secretions. Within a 
more comprehensive classification of chronic respi-
ratory failure (Chart 2), we can characterize it as a 
profile of chronic restrictive respiratory failure with 
hypoventilation.
There have been no large prospective studies 
addressing this specific topic. Nevertheless, it is 
possible to establish a minimum routine of peri-
odical evaluation (Figure 3) in order to introduce 
pertinent therapeutic measures for each stage of 
the disease. In addition, all therapeutic possibilities 
should be presented to the patient and their family, 
so that joint decisions can be duly implemented.
The loss of respiratory muscle strength leads to 
cough inefficacy and hypoventilation. Atelectasis, 
pneumonia and respiratory failure, initially during 
sleep and later on even during wakefulness, are 
the complications expected in this situation. The 
adequate frequency of evaluations of the respiratory 
system of these patients has not been established 
and depends a great deal on the speed of the 
progression of the symptoms and on the deteriora-
tion of pulmonary function.
Spirometry, pulse oximetry and capnography, 
together with measurements of peak cough flow, 
maximal inspiratory pressure and maximal expira-
tory pressure, make it possible for the physician to 
predict which patients will require assisted cough 
techniques and ventilatory support.
Functionally, patients with neuromuscular 
diseases present decreases in vital capacity and 
total lung capacity. However, these are not sensi-
tive parameters in the evaluation of respiratory 
muscle strength of these individuals, since vital 
capacity can remain above the normal limits even 
if there has already been severe muscle strength 
impairment, which can be detected by the meas-
urements of maximal static respiratory pressures. 
Chart 2 - Classification of chronic respiratory failure.
Chronic obstructive respiratory failure Associated diseases
Chronic restrictive respiratory failure COPD, bronchiectasis and other forms of bronchiolitis
With hyperventilation Interstitial diseases, such as idiopathic pulmonary fibrosis, fibrogenic 
pneumoconioses
With hypoventilation Neuromuscular diseases and thoracic deformities
Chronic respiratory failure caused by 
pulmonary vascular disease
Primary pulmonary hypertension, other forms of precapillary pulmonary 
hypertension, pulmonary veno-occlusive disease, chronic pulmonary 
thromboembolism
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Vital capacity ?1.5 L or ?50% of 
predicted and MIP ?60% of predicted
Vital capacity ?1.2-1.5 L or
?40-50% of predicted and 
MIP ?60% of predicted
Probable indication of
noninvasive ventilation
Repeat exams periodically, according 
to the rate of progression of the 
neuromuscular disease in question
Gasometry
arterial or capnography
PaCO2 ?45 mmHg or
end tidal CO2 ?50 mmHg
Polysomnography
Normal
Respiratory alterations during sleep or 
SpO2 ?88% for over 5 min
If vital capacity in two 
positions (sitting and supine) 
drops by ?40%
If PCF <270 L/min
Assisted 
cough
Asymptomatic Symptomatic
Detailed history and 
physical examination
SymptomaticAsymptomatic
Spirometry, MIP and MEP and PCF
PaCO2 <45 mmHg or
end tidal CO2 <50 mmHg
Figure 3 - Protocol for functional evaluation of patients with neuromuscular diseases. MIP: maximal inspiratory 
pressure; MEP: maximal inspiratory pressure; PCF: peak cough flow; PaCO2: arterial carbon dioxide tension; ETCO2: end-
tidal carbon dioxide; SpO2: peripheral oxygen saturation (via pulse oximetry).
Only when muscle weakness is significant (reduc-
tions in force to less than 50% of predicted) can a 
decrease in vital capacity be observed.(15) However, 
it is a useful examination in the follow-up of more 
critical patients whose muscle weakness is suffi-
cient to reduce vital capacity. When vital capacity 
drops to below the 40–50% of predicted range, the 
possibility of evaluating arterial gases during wake-
fulness should be considered, even in asymptomatic 
patients.(16)
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Many different values are mentioned in the 
literature, according to which impaired pulmo-
nary function increases the risk of complications 
and death.(17) In patients with Duchenne muscular 
dystrophy, the variable that correlates most signifi-
cantly with decreased survival is vital capacity lower 
than 1 L, and forced expiratory volume in one 
second lower than 20% of the predicted value is 
associated with hypercapnia during wakefulness 
periods.(18)
Therefore, in each respiratory evaluation, it is 
recommended that the following be performed: 
pulse oximetry; measurements of vital capacity 
and forced expiratory volume in one second in 
two positions (sitting and in the dorsal decubitus 
position), in order to make the test more sensitive; 
measurement of maximal inspiratory and maximal 
expiratory pressures; and the determination of peak 
cough flow.
When normal individuals are submitted to 
spirometry in the supine position, the vital capacity 
values obtained are equal to or even greater than 
those obtained when the individual is evaluated 
in a sitting position. The potential increase in the 
force of the diaphragm in the supine position can 
result from the muscle distention due to the move-
ment of the abdominal content upwards. Patients 
whose diaphragm force is impaired by some disease 
would have much more difficulty in exhaling force-
fully when in the dorsal decubitus position. A 40% 
or greater reduction in the forced vital capacity 
measured in the supine decubitus position is highly 
indicative of significantly impaired performance 
of the diaphragm in this position, thereby making 
ventilation considerably less effective during sleep. 
However, any drop of 20% or greater should alert 
the physician to the need to study respiratory 
performance during sleep.(19)
The measurement of peak cough flow can be 
made with the aid of a peak flow meter (Figure 4).
Peak cough flow is directly correlated with the 
capacity to clear secretions from the respira-
tory system,(20) and values lower than 160 L/min 
are associated with inadequate clearance of the 
tracheobronchial tree.(21,22) However, values greater 
than, but proximal to, 160 L/min do not neces-
sarily guarantee adequate protection of the airways, 
since muscle force tends to worsen during episodes 
of infection.(23) Therefore, a peak cough flow cut-
off value of 270 L/min has been used to identify 
patients who would benefit from assisted cough 
techniques.(24)
Maximal expiratory pressure values of 60 cmH2O
or greater are associated with the capacity to 
generate adequate airflows during cough, whereas 
measurements equal to or lower than 45 cmH2O
are correlated with inefficacious cough.(25) Pulse 
oximetry helps to identify situations such as atel-
ectasis and pneumonias, in which it is necessary to 
intensify the secretion clearance measures.(24)
Carbon dioxide in the blood should also be 
determined, and capnography-based estimates 
are ideal for this purpose. The routine follow-up 
evaluation of patients with neuromuscular diseases 
does not include arterial blood gas analysis. When 
capnography is unavailable, a venous blood sample 
or capillary blood sample obtained by skin puncture 
should be used. Annual chest X rays facilitate the 
detection of the sequelae of parenchymal lesions, 
and determining hematocrit levels can further the 
evaluation of the severity of hypoxemia and of the 
efficiency of the treatment.
In addition, patients should also be tested for 
other respiratory or associated disorders, such as 
obstructive sleep apnea, aspiration, gastroesopha-
geal reflux and asthma.
A nutritional evaluation can be helpful in 
controlling obesity related to low caloric expendi-
ture, as well as in minimizing muscle mass loss 
related to the disease or to a sedentary life style. 
The body mass index should be periodically deter-
mined, as should, if possible, the distribution of lean 
mass and body fat, through the use of appropriate 
techniques (impedanciometry or nuclear medicine). 
Figure 4 - Digital peak expiratory flow meter.
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If appropriate oral nutrition cannot be guaranteed, 
enteral feeding or gastrostomy should be consid-
ered. Swallowing should be evaluated based on the 
clinical history and direct observation of the capacity 
of the patient to swallow food of various textures. 
Fluoroscopy should be used if there is a history of 
suffocation sensation or dysphagia.
Neuromuscular diseases can produce sleep alter-
ations, since alveolar hypoventilation is more intense 
during sleep. The worsening of alveolar air exchange 
presents subtle symptoms that can pass unnoticed if 
not directly analyzed. Hypoventilation during sleep 
can initially manifest as a progressively increasing 
number of nighttime awakenings, fatigue, daytime 
sleepiness and morning headaches.
The phase in which polysomnography is indi-
cated in patients with neuromuscular disease has 
yet to be established. Therefore, symptoms related 
to sleep disorders should always be investigated. 
In the presence of symptoms, independently of 
concomitant daytime hypercapnia, polysomnog-
raphy should be performed. If polysomnography is 
unavailable, the continuous monitoring of oxygen 
saturation and expired carbon dioxide (oximetry and 
capnography) can aid in the management of these 
patients. In the absence of this type of monitoring, 
determining the levels of carbon dioxide in capil-
lary or arterial blood upon waking can be useful. 
Asymptomatic patients with daytime hypercapnia 
or severe pulmonary function disorders should be 
submitted to polysomnography. It should be noted 
that this examination can be used in the titration of 
the pressure levels at the beginning of the ventila-
tion with positive pressure support.
Techniques for lung inflation and airway 
clearance
If the evaluation of the peak cough flow and 
expiratory muscle strength suggests a situa-
tion of inadequate clearance of airway secretions, 
techniques aimed at facilitating the clearance of 
secretions should be introduced.
Maximum inflation capacity is the maximum 
volume of air that can be held inside the lung with 
a closed glottis, and it depends on the muscle force 
of the pharynx and larynx. The increased air volume 
in the lungs results in greater expiratory volume, 
which helps the patient generate efficacious expira-
tory flows for the mobilization of secretions.(26)
Maximum inflation capacity can be achieved when 
a series of inspiratory maneuvers are performed 
without exhaling in between, in order to accumu-
late air in the lungs.
Glossopharyngeal breathing consists in using the 
muscle of the base of the tongue and pharynx in 
order to push the air contained inside the oropharynx 
and nasopharynx toward the larynx and trachea.
There are other techniques of pulmonary infla-
tion and airway clearance: pulmonary inflation with 
an Ambu bag and mask; pulmonary inflation with 
noninvasive pressure support devices; and pulmonary 
inflation with conventional mechanical ventilators, 
used in an invasive or noninvasive form.
All of these techniques to increase inspiratory 
volume should be used with manually assisted 
cough, a situation in which the physical therapist 
or caretaker pushes the diaphragm of the patient 
upward with one hand and compresses the anterior 
aspect of the chest with the other, in synchrony with 
the cough efforts made by the patient, if possible.
For patients presenting little or no force 
to cough, it is formally recommended to use a 
device capable of producing inflation with posi-
tive pressure and aspiration with negative pressure 
immediately after lung expansion. This device is 
known as IN-Exsufflator or Cough Assist (Figure 5).
The comparison between the peak cough flows 
produced with these machines and those produced 
by maximum inflation and assisted cough reveals 
the superiority of the mechanical reproduction of 
Figure 5 - Cough machine (Cough Assist).
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cough. Indeed, the use of one of these machines 
significantly facilitates the care of patients with 
neuromuscular disease, even in the early stages of 
respiratory muscle strength impairment.
Percussive ventilation, which involves high-
frequency pulses of air and low tidal volume while 
maintaining continuous positive pressure in the 
airways, seems to be efficacious in reversing persistent 
atelectasis in children.(27) The high frequency oscilla-
tion of the chest wall is also a possible technique for 
the mobilization of secretions. However, like percus-
sive ventilation, it works better in patients whose 
muscle strength is more preserved. Bronchoscopy 
should be used only if the other maneuvers fail.
Noninvasive nocturnal pressure support
The diagnosis of nocturnal hypoventilation calls 
for the use of noninvasive pressure support. The 
use of a bi-level positive pressure device, or of a 
conventional mechanical ventilator with nasal or 
oronasal mask, has proven efficacious in reversing 
sleep-disordered breathing in various neuromuscular 
diseases(28,29) The value of positive pressure capable 
of reversing hypoventilation during sleep should 
be determined in the sleep laboratory or through 
careful observation and monitoring at the bedside. 
In addition, if the underlying disease is progressive, 
the possible need to periodically increase the pres-
sure values should be emphasized.
Noninvasive nocturnal pressure support can 
increase survival in some patients,(30,31) improve sleep 
quality, decrease daytime sleepiness, increase the 
sense of well-being/independence, improve diurnal 
blood gases and decrease the rate of decline in lung 
function.(31-36)
The complications of the noninvasive pressure 
support using a full face mask include conjuncti-
vitis, skin ulcers, gastric distension and aspiration 
of vomit. Problems with eyes and facial skin can be 
prevented if the mask is appropriately fitted. Nasal 
obstruction, a quite common complaint among 
patients under noninvasive pressure support with a 
nasal mask, can be improved by humidifying the 
air supply and by the use of nasal corticosteroids. 
Generally speaking, when used in the support of 
patients with neuromuscular diseases, the machines 
that provide two pressure levels (BiPAP and similar 
devices) should necessarily offer the possibility 
of starting with a controlled mode respiratory 
frequency, in case the patient stops breathing 
completely (back-up ventilation). In addition, since 
these devices are used without alarms, nocturnal 
oximetry monitoring, with alarm, is recommended.
In patients with neuromuscular diseases, oxygen 
should never be used without appropriate ventila-
tory support.
Extending the pressure ventilation 
support to the diurnal period
Extending the ventilation to the diurnal period 
should be considered if the patient presents arte-
rial carbon dioxide tension greater than 50 mmHg, 
or oxygen saturation by pulse oximetry lower than 
92% while awake.
More comfort for the patient is achieved with 
intermittent ventilation with positive pressure, using 
a mouthpiece. Therefore, any home mechanical 
ventilator, capable of guaranteeing adequate tidal 
volumes, can be used in the assist/control mode. 
The machine can be adapted to a wheelchair, and 
the circuit, with the mouthpiece, is connected to a 
support near the mouth of the patient. Whenever 
necessary, the patient moves the neck, holds the 
mouthpiece with the teeth and waits for an infla-
tion of the equipment (or triggers the inflation, if 
capable). Obviously, this type of ventilatory support 
presupposes adequate function of the bulbar and 
neck muscles. Mouthpieces fixed to the teeth permit 
the use of this same type of ventilation during the 
nocturnal period.
Tracheostomies should only be recommended 
in situations of absolute intolerance of noninvasive 
ventilation or in case of severe impairment of the 
bulbar muscles. Even in the latter, we can still insist 
on the noninvasive pressure support, provided that 
a mechanically assisted cough machine and a pulse 
oximeter are available. Tracheostomies hinder the 
normal defense mechanisms of the trachea, increase 
secretion, rapidly colonize with difficult to control 
germs, impede swallowing and impair speech (unless 
speaking valves, which are costly, are used).
Final considerations
Neuromuscular disease patients and their fami-
lies should be presented with all of the therapeutic 
possibilities. Each treatment recommendation should 
be thoroughly discussed. There is no technical or 
ethical justification for making any decision against 
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the wishes of the patient, nor should physicians use 
their own values to decide what an acceptable level 
of quality of life is for another person. 
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